A practical reference on CJC-1295: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 3.4 to 3.6 kDa | Depends on whether the affinity complex is attached |
| Appearance | White to off-white lyophilized powder | Freeze-dried solid, often in a sealed vial |
| Solubility | Soluble in water and aqueous buffers | Dissolution rate varies with pH and buffer salt |
| Typical storage | Below minus 20 degrees Celsius, dry and dark | Dissolved material is usually kept cold and used promptly |
| Common analytical methods | Reversed-phase HPLC and mass spectrometry | Peptide mapping and amino acid analysis add sequence detail |
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
Confluentic acid is an organic compound belonging to the chemical class known as depsides. It serves as a secondary metabolite in certain lichens and plays a role in distinguishing closely related species within the genus Porpidia. In 1899, Friedrich Wilhelm Zopf isolated a compound from Lecidea confluens, which he initially named confluentin and noted for its melting point of 147–148 °C. This substance demonstrated the ability to turn litmus paper red and, when interacting with alkali, decomposed into carbon dioxide and phenol-like compounds. Zopf subsequently revised the chemical formula and melting point of the compound. Siegfried Huneck renamed it confluentinic acid in 1962, characterising it as optically inactive, with distinct colour reactions and solubility properties, and determined its molecular formula as C28H36O8. Confluentic acid can be identified using thin-layer chromatography and high-performance liquid chromatography. An alternative visual detection method involves examining the lichen's thallus or apothecium (fruiting body) under a microscope on a slide treated with potassium hydroxide, which reveals oil droplets indicative of confluentic acid. Several structural analogues of confluentic acid have been isolated from a variety of lichen species.
Cardiac troponin C (cTnC) TNNC1 is expressed in cardiac and slow skeletal muscle, while skeletal troponin C (sTnC) TNNC2 is expressed in fast skeletal muscle. sTnC has four calcium ion-binding sites, whereas in cTnC there are only three. The actual amount of calcium that binds to troponin has not been definitively established. Because slow skeletal muscle and myocardium share a type, TnC is not used in diagnostics. Mammals have three troponin I (TnI) genes: the cardiac (TNNI3, cTnI), the slow skeletal (TNNI1), and the fast skeletal (TNNI2). Because the heart uses its own version, blood levels of cTnI is used as a clinical marker. Mammals have three troponin T (TnT) genes: the cardiac (TNNT2, cTnT), the slow skeletal (TNNT1), and the fast skeletal (TNNT3). Again, because the heart uses its own version, cTnT is used as a clinical marker. In addition to the myocardium, there are reports of CTnI and CTnT expression in the wall muscle coat of the vena cava and pulmonary veins, so they do not purely originate from the heart. The expression of cTnT in skeletal tissue of patients with chronic skeletal muscle injuries has been described.
In order to strengthen security and stability in Iraq, and thereby contribute to international peace and stability, and to enhance the ability of the Republic of Iraq to deter all threats against its sovereignty, security, and territorial integrity, the Parties shall continue to foster close cooperation concerning defense and security arrangements without prejudice to Iraqi sovereignty over its land, sea, and air territory.
=== Eggs and hatchlings === C. brunneus lay eggs in a variety of habitats from chalk hills to sandy hills but most commonly lay their eggs in sandy, dry habitats. In the lab, C. brunneus prefer dry and compact substrates composed of fine particles such as sand. They produce the largest number of eggs between 28-35 °C degrees. In theory, smaller eggs should have higher mortality rates because of reduced provisions provided within the egg. However researchers found that egg viability is greater in the southern populations where eggs are smaller. This can be explained by higher overwintering temperatures. Egg size is influenced by a number of factors. As maternal age increases so does egg size. At the beginning of the breeding season females lay smaller eggs compared to the end of the breeding season. Eggs laid in the last part of the breeding season are smaller in size due to deteriorating maternal health. Research suggests that there is no correlation between stage of development and water uptake. While eggs can withstand a large amount of water loss they cannot survive complete desiccation. Therefore, it is not important at what point water is absorbed, it is only important that water is absorbed at some point. A larger egg size generally results in a larger hatchling and adult size. Eggs laid by C. brunneus from late August to early September are the heaviest, hatch the latest, and have heavier hatchlings. While earlier hatchlings are initially smaller, earlier hatchlings achieve a larger body size than later hatchlings.
Sources: en.wikipedia.org
=== X-ray emission === Quantum theory states that orbiting electrons of an atom must occupy discrete energy levels in order to be stable. Bombardment with ions of sufficient energy (usually MeV protons) produced by an ion accelerator, will cause inner shell ionisation of atoms in a specimen. Outer shell electrons drop down to replace inner shell vacancies; however, only certain transitions are allowed. X-rays of a characteristic energy of the element are emitted. An energy-dispersive detector is used to record and measure these X-rays. Only elements heavier than fluorine can be detected. The lower detection limit for a PIXE beam is given by the ability of the X-rays to pass through the window between the chamber and the X-ray detector. The upper limit is given by the ionisation cross section, the probability of the K electron shell ionisation, is maximal when the velocity of the proton matches the velocity of the electron (10% of the speed of light), therefore 3 MeV proton beams are optimal.
=== Pharmacokinetics === Nedaplatin is administered in its active form and is removed from the bloodstream by the kidneys to leave the body via the urine. The recommended therapeutic dose of nedaplatin is 80–100 mg/m2 of body surface area. Optimal dosing is determined using measurements of unbound platinum concentrations following intravenous infusion together with an assessment of renal function using creatinine clearance. The dose can be estimated using Ishibashi’s formula: DoseNDP = AUC × CLNDP, where CLNDP = 0.0738 × creatinine clearance + 4.47 The precise mechanism of cellular uptake is not fully understood, and substantially less information is available compared with cisplatin. However, nedaplatin does not interact with the Oct2 transporter or apical multidrug and toxin extrusion (MATE) transporters, which may contribute to its lower accumulation in renal proximal tubules.
Animation – Dispatch Artistic Achievement – Death Stranding 2: On the Beach Audio Achievement – Dispatch Best Game – Clair Obscur: Expedition 33 British Game – Atomfall Debut Game – Clair Obscur: Expedition 33 Evolving Game – No Man's Sky Family – Lego Party Game Beyond Entertainment – Despelote Game Design – Blue Prince Multiplayer – ARC Raiders Music – Ghost of Yōtei Narrative – Kingdom Come: Deliverance II New Intellectual Property – South of Midnight Performer in a Leading Role – Jennifer English as Maelle in Clair Obscur: Expedition 33 Performer in a Supporting Role – Jeffrey Wright as Chase in Dispatch Technical Achievement – Ghost of Yōtei
Sources: en.wikipedia.org
== External links == Extension Toxicology Network: Chlorothalonil Pesticide Information Profile Chlorothalonil in the Pesticide Properties DataBase (PPDB) "2017 Pesticide Use Maps - Low". Water Resources. United States Geological Survey. Retrieved 16 March 2021. "2017 Pesticide Use Maps - High". Water Resources. United States Geological Survey. Retrieved 16 March 2021.
is chosen to represent the change in potential energy per unit charge flowing into the cell as above. Furthermore, due to redox-driven proton pumping by coupling sites, the proton gradient is always inside-alkaline. For both of these reasons, protons flow in spontaneously, from the P side to the N side; the available free energy is used to synthesize ATP (see below). For this reason, PMF is defined for proton import, which is spontaneous. PMF for proton export, i.e., proton pumping as catalyzed by the coupling sites, is simply the negative of PMF(import). The spontaneity of proton import (from the P to the N side) is universal in all bioenergetic membranes. This fact was not recognized before the 1990s, because the chloroplast thylakoid lumen was interpreted as an interior phase, but in fact it is topologically equivalent to the exterior of the chloroplast. Azzone et al. stressed that the inside phase (N side of the membrane) is the bacterial cytoplasm, mitochondrial matrix, or chloroplast stroma; the outside (P) side is the bacterial periplasmic space, mitochondrial intermembrane space, or chloroplast lumen. Furthermore, 3D tomography of the mitochondrial inner membrane shows its extensive invaginations to be stacked, similar to thylakoid disks; hence the mitochondrial intermembrane space is topologically quite similar to the chloroplast lumen.: The energy expressed here as Gibbs free energy, electrochemical proton gradient, or proton-motive force (PMF), is a combination of two gradients across the membrane:
Subglandular implant-pocket: The plastic surgeon emplaces the breast implant to the retromammary space — between the breast tissue and the pectoralis major muscle — which is the orientation that most approximates the normal plane of the breast. Although this surgical approach to emplacing a prosthetic breast yields the most aesthetic results, in women with a small volume of soft-tissue in the breast, the subglandular emplacement of the implant is likelier to ripple and wrinkle the skin-envelope of the breast. Subfascial implant-pocket: The surgeon emplaces the prosthetic breast beneath the fascia (the membrane that covers and encloses the pectoralis major muscle) to augment the size and volume of the breast hemisphere, for subsequent contouring and anatomic symmetry. Subpectoral implant-pocket: In this dual-plane surgical approach, the surgeon emplaces the breast implant beneath the pectoralis major muscle (after partially cutting the inferior attachments of that muscle) with or without the partial cutting of the subglandular plane of the breast. Resultantly, the upper-half of the breast-implant is partially beneath the pectoralis major muscle, while the lower-half of the implant is in the subglandular plane of the breast being augmented. This emplacement technique achieves maximal coverage of the upper-half of the breast implant, whilst allowing the maximal expansion of the lower-half of the implant to achieve maximal breast-volume; however, there exists the risk of animation deformity, the breast-implant moving in place beneath the subpectoral plane.
== History == DESI has been widely studied since its inception in 2004 by Zoltan Takáts, Justin Wiseman and Bogdan Gologan, in Graham Cooks' group from Purdue University with the goal of looking into methods that didn't require the sample to be inside of a vacuum. Both DESI and direct analysis in real time (DART) have been largely responsible for the rapid growth in ambient ionization techniques, with a proliferation of more than eighty new techniques being found today. These methods allow for complex systems to be analyzed without preparation and throughputs as high as 45 samples a minute. DESI is a combination of popular techniques, such as, electrospray ionization and surface desorption techniques. Electrospray ionization with mass spectrometry was reported by Malcolm Dole in 1968, but John Bennett Fenn was awarded a nobel prize in chemistry for the development of ESI-MS in the late 1980s. Then in 1999, desorption of open surface and free matrix experiments were reported in the literature utilizing an experiment that was called desorption/ionization on silicon. The combination of these two advancements led to the introduction of DESI and DART as the main ambient ionization techniques that would later become multiple different techniques. One in particular, due to increasing studies into optimization of DESI, is nanospray desorption electrospray ionization (nano-DESI). In this technique the analyte is desorbed into a liquid bridge formed between two capillaries and the analysis surface.
Sources: en.wikipedia.org
The version carrying the affinity complex bears a maleimide group that binds serum albumin, which extends its circulation time to several days. The version without it lacks this group and clears within roughly half an hour. The two are chemically related but behave very differently once in the body.
In common usage the name without the affinity complex is often equated with MOD GRF 1-29, a fragment carrying four stabilizing substitutions. Strictly speaking, the term originally referred to the albumin-binding version. The overlap in naming causes frequent ambiguity in both informal and technical writing.
Reversed-phase chromatography separates the peptide from related impurities and yields a purity estimate. Mass spectrometry confirms the molecular mass and detects modifications such as oxidation. Sequence-level checks rely on peptide mapping or amino acid analysis when stronger confirmation is needed.
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.